{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:41:12Z","timestamp":1785404472147,"version":"3.56.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0158140","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T15:52:52Z","timestamp":1467301972000},"page":"e0158140","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)"],"prefix":"10.1371","volume":"11","author":[{"given":"Matthew H.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7773-3144","authenticated-orcid":false,"given":"David L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Lumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaswinder","family":"Samra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/erc.0.0110001","article-title":"Neuroendocrine tumours","volume":"11","author":"MT Barakat","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after &quot;carcinoid&quot;: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"JC Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"JK Ramage","year":"2012","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"MH Kulke","year":"2010","journal-title":"Pancreas"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000335629","article-title":"ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas","volume":"95","author":"UF Pape","year":"2012","journal-title":"Neuroendocrinology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000335587","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors","volume":"95","author":"M Falconi","year":"2012","journal-title":"Neuroendocrinology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/CCO.0b013e328011a236","article-title":"Functioning and nonfunctioning neuroendocrine tumors of the pancreas","volume":"19","author":"E Dixon","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0b013e3282f1c595","article-title":"Neuroendocrine tumors of the diffuse neuroendocrine system","volume":"20","author":"BI Gustafsson","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"ref9","first-page":"82","article-title":"Effect of carbamoylation on the repair of nitrosourea-induced DNA alkylation damage in L1210 cells","volume":"39","author":"JM Heal","year":"1979","journal-title":"Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(68)91058-1","article-title":"Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin","volume":"2","author":"IM Murray-Lyon","year":"1968","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","article-title":"Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients","volume":"79","author":"LE Broder","year":"1973","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/1097-0142(197508)36:2+<675::AID-CNCR2820360810>3.0.CO;2-A","article-title":"Clinical management of advanced gastrointestinal cancer","volume":"36","author":"CG Moertel","year":"1975","journal-title":"Cancer"},{"key":"ref13","first-page":"49","article-title":"Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?","volume":"72","author":"T Delaunoit","year":"2009","journal-title":"Acta Gastroenterologica Belgica"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1517\/14656566.9.15.2617","article-title":"Pharmacotherapy of neuroendocrine cancers","volume":"9","author":"IM Modlin","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.humpath.2011.06.011","article-title":"Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors","volume":"43","author":"D Dhall","year":"2012","journal-title":"Hum Pathol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1196\/annals.1294.002","article-title":"The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification","volume":"1014","author":"G Kloppel","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"ref17","article-title":"Handbook for Systematic Reviews of Interventions Version 5.0.1","author":"J Higgins","year":"2011"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/0277-5379(89)90107-7","article-title":"Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon","volume":"25","author":"K \u00d6berg","year":"1989","journal-title":"European Journal of Cancer and Clinical Oncology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group","volume":"27","author":"A Rinke","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"PF Engstrom","year":"1984","journal-title":"Journal of Clinical Oncology"},{"key":"ref21","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"CG Moertel","year":"1979","journal-title":"Cancer Clinical Trials"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"CG Moertel","year":"1980","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"CG Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281","volume":"23","author":"W Sun","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ejca.2013.12.011","article-title":"Capecitabine and streptozocin +\/- cisplatin in advanced gastroenteropancreatic neuroendocrine tumours","volume":"50","author":"T Meyer","year":"2014","journal-title":"Eur J Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1677\/ERC-09-0104","article-title":"Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710","volume":"16","author":"L Dahan","year":"2009","journal-title":"Endocrine-Related Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"RT Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","article-title":"Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting","volume":"29","author":"MH Kulke","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"IM Modlin","year":"2008","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"ref30","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/annonc\/12.suppl_2.S69","article-title":"Clinical significance of blood chromogranin A measurement in neuroendocrine tumours","volume":"12","author":"E Seregni","year":"2001","journal-title":"Ann Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"H Sorbye","year":"2013","journal-title":"Ann Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"ME Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"JC Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"ref34","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","author":"JC Yao","year":"2015","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"S Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"MH Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"JR Strosberg","year":"2011","journal-title":"Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0158140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T22:58:25Z","timestamp":1540335505000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0158140"}},"subtitle":[],"editor":[{"given":"Salomon M","family":"Stemmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0158140","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}